Cargando…

Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection

BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by SFTS virus and characterized by a high case fatality rate. Currently, there is no effective therapy for the disease. While the administration of ribavirin does not improve the case fatality rate o...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimojima, Masayuki, Fukushi, Shuetsu, Tani, Hideki, Taniguchi, Satoshi, Fukuma, Aiko, Saijo, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630909/
https://www.ncbi.nlm.nih.gov/pubmed/26527529
http://dx.doi.org/10.1186/s12985-015-0412-3
_version_ 1782398790068600832
author Shimojima, Masayuki
Fukushi, Shuetsu
Tani, Hideki
Taniguchi, Satoshi
Fukuma, Aiko
Saijo, Masayuki
author_facet Shimojima, Masayuki
Fukushi, Shuetsu
Tani, Hideki
Taniguchi, Satoshi
Fukuma, Aiko
Saijo, Masayuki
author_sort Shimojima, Masayuki
collection PubMed
description BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by SFTS virus and characterized by a high case fatality rate. Currently, there is no effective therapy for the disease. While the administration of ribavirin does not improve the case fatality rate or viral load in patient blood, it can inhibit viral infection in vitro. METHODS: Vero cells were pre-treated with interferons (IFNs) α, β, and γ alone and in combination with ribavirin drugs and inoculated with SFTS virus. Three days later, supernatants were harvested and subjected to virus titration. An unpaired t-test was used for statistical analysis of the drugs’ effects. RESULTS: While the effects of IFNγ at high concentrations were slightly weaker than those of the other IFNs, all IFNs showed dose-dependent inhibitory effects. The combined usage of IFNs with ribavirin at 90 % effective concentrations showed large inhibitory effects, with over a 3 log(10) reduction in viral titers. CONCLUSIONS: The combined usage of one of type-I/II IFNs with ribavirin drastically reduced SFTS virus infection and therefore may be useful in the treatment of SFTS.
format Online
Article
Text
id pubmed-4630909
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46309092015-11-04 Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection Shimojima, Masayuki Fukushi, Shuetsu Tani, Hideki Taniguchi, Satoshi Fukuma, Aiko Saijo, Masayuki Virol J Research BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by SFTS virus and characterized by a high case fatality rate. Currently, there is no effective therapy for the disease. While the administration of ribavirin does not improve the case fatality rate or viral load in patient blood, it can inhibit viral infection in vitro. METHODS: Vero cells were pre-treated with interferons (IFNs) α, β, and γ alone and in combination with ribavirin drugs and inoculated with SFTS virus. Three days later, supernatants were harvested and subjected to virus titration. An unpaired t-test was used for statistical analysis of the drugs’ effects. RESULTS: While the effects of IFNγ at high concentrations were slightly weaker than those of the other IFNs, all IFNs showed dose-dependent inhibitory effects. The combined usage of IFNs with ribavirin at 90 % effective concentrations showed large inhibitory effects, with over a 3 log(10) reduction in viral titers. CONCLUSIONS: The combined usage of one of type-I/II IFNs with ribavirin drastically reduced SFTS virus infection and therefore may be useful in the treatment of SFTS. BioMed Central 2015-11-02 /pmc/articles/PMC4630909/ /pubmed/26527529 http://dx.doi.org/10.1186/s12985-015-0412-3 Text en © Shimojima et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Shimojima, Masayuki
Fukushi, Shuetsu
Tani, Hideki
Taniguchi, Satoshi
Fukuma, Aiko
Saijo, Masayuki
Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
title Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
title_full Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
title_fullStr Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
title_full_unstemmed Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
title_short Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
title_sort combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630909/
https://www.ncbi.nlm.nih.gov/pubmed/26527529
http://dx.doi.org/10.1186/s12985-015-0412-3
work_keys_str_mv AT shimojimamasayuki combinationeffectsofribavirinandinterferonsonseverefeverwiththrombocytopeniasyndromevirusinfection
AT fukushishuetsu combinationeffectsofribavirinandinterferonsonseverefeverwiththrombocytopeniasyndromevirusinfection
AT tanihideki combinationeffectsofribavirinandinterferonsonseverefeverwiththrombocytopeniasyndromevirusinfection
AT taniguchisatoshi combinationeffectsofribavirinandinterferonsonseverefeverwiththrombocytopeniasyndromevirusinfection
AT fukumaaiko combinationeffectsofribavirinandinterferonsonseverefeverwiththrombocytopeniasyndromevirusinfection
AT saijomasayuki combinationeffectsofribavirinandinterferonsonseverefeverwiththrombocytopeniasyndromevirusinfection